Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Int J Clin OncolJul 2, 2026 (epub)
Yuko Shirouchi, Yuko Mishima, Suguru Fukuhara et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase I study evaluated the safety, pharmacokinetics, and efficacy of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Eight patients were enrolled, with an overall response rate of 75.0%. The study found a manageable safety profile, with no grade 5 adverse events reported.
Key findings
- Overall response rate was 75.0% (6/8 patients).
- Complete response rate was 100% in Cohort 2 (3/3 patients).
- Seven patients experienced grade 3/4 adverse events.
- Cytokine release syndrome occurred in all glofitamab-treated patients.
Why it matters
The findings suggest that glofitamab may be a promising treatment option for Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma, highlighting its potential role in managing this challenging patient population.